Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-Asprosin (human), mAb (Birdy-2)
Product Details | |
---|---|
Synonyms | Fibrillin-1 C-terminal Cleavage Product; FBN1 C Terminal Cleavage Product |
Product Type | Monoclonal Antibody |
Properties | |
Clone | Birdy-2 |
Isotype | Mouse IgG2a |
Source/Host | Purified from concentrated hybridoma tissue culture supernatant. |
Immunogen/Antigen | Recombinant human asprosin. |
Application |
Western Blot: (1:1'000) |
Crossreactivity | Human |
Specificity |
Recognizes human asprosin and human fibrillin-1 (by homology). This antibody can detect pro-fibrillin-1 in cell extracts. Only asprosin is detected in supernatant or plasma/serum, but not pro-fibrillin-1 since the C-terminal part encoding for asprosin is cleaved by the protease furin upon secretion. |
Purity | ≥95% (SDS-PAGE) |
Purity Detail | Protein A affinity purified. |
Concentration | 1mg/ml |
Formulation | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
Isotype Negative Control | |
Other Product Data |
Uniprot. Human Fibrillin-1 |
Accession Number | Fibrillin-1: P35555 |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
Asprosin is a new fasting-induced protein hormone that targets the liver to increase plasma glucose levels. Asprosin is the C-terminal cleavage product of the protein Fibrillin-1. Asprosin is secreted from white adipose tissue and increases hepatic glucose production by using cAMP as a second messenger, leading to activation of protein Kinase A. Reduction of Asprosin levels protects against metabolic syndrome-associated hyperinsulinism. Asprosin may act as a circulating hunger signal. Indeed, peripherally injected recombinant asprosin can cross the blood-brain barrier and intracerebroventricular (i.c.v.) injection of recombinant asprosin stimulated appetite in wild-type mice, indicating a central mechanism of action. Loss of Asprosin in mice and human leads to decreased fat mass and body weight, and hypophagia. Mice are also completely protected from the development of diet-induced obesity. Asprosin works by stimulating the orexigenic AgRP+ (Agouti related neuropeptide) neurons via a cAMP-dependent pathway and by inhibiting the anorexigenic neurons POMC+ (pro-opiomelanocortin) neurons in a GABA-dependent manner. Mutation in Asprosin in human leads to the pattern of metabolic dysregulation, including partial lipodystrophy, accompanied by reduced plasma insulin. Due to its key role in food regulation, Asprosin function could serve as a potentially unique therapeutic target against obesity, diabetes or metabolic diseases.
- Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study: L. Zhong, et al.; Placenta 93, 17 (2020)